Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Biofrontera (BFRI) EBITDA Margin (2020 - 2025)

Historic EBITDA Margin for Biofrontera (BFRI) over the last 6 years, with Q3 2025 value amounting to 89.84%.

  • Biofrontera's EBITDA Margin fell 348000.0% to 89.84% in Q3 2025 from the same period last year, while for Sep 2025 it was 47.4%, marking a year-over-year increase of 73600.0%. This contributed to the annual value of 46.11% for FY2024, which is 204400.0% up from last year.
  • Per Biofrontera's latest filing, its EBITDA Margin stood at 89.84% for Q3 2025, which was down 348000.0% from 56.25% recorded in Q2 2025.
  • Over the past 5 years, Biofrontera's EBITDA Margin peaked at 13.63% during Q4 2024, and registered a low of 371.6% during Q3 2021.
  • Over the past 5 years, Biofrontera's median EBITDA Margin value was 62.89% (recorded in 2023), while the average stood at 81.13%.
  • Its EBITDA Margin has fluctuated over the past 5 years, first crashed by -2995200bps in 2021, then soared by 2874000bps in 2022.
  • Quarter analysis of 5 years shows Biofrontera's EBITDA Margin stood at 20.51% in 2021, then plummeted by -168bps to 55.02% in 2022, then surged by 34bps to 36.48% in 2023, then soared by 63bps to 13.63% in 2024, then plummeted by -559bps to 89.84% in 2025.
  • Its last three reported values are 89.84% in Q3 2025, 56.25% for Q2 2025, and 52.95% during Q1 2025.